Propanc Biopharma (Propanc Biopharma) Debt-to-Equity : -0.29 (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Propanc Biopharma Debt-to-Equity?

Propanc Biopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.98 Mil. Propanc Biopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.04 Mil. Propanc Biopharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-3.56 Mil. Propanc Biopharma's debt to equity for the quarter that ended in Dec. 2023 was -0.29.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Propanc Biopharma's Debt-to-Equity or its related term are showing as below:

PPCB' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.73 Med: -0.39 Max: -0.06
Current: -0.29

During the past 13 years, the highest Debt-to-Equity Ratio of Propanc Biopharma was -0.06. The lowest was -0.73. And the median was -0.39.

PPCB's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs PPCB: -0.29

Propanc Biopharma Debt-to-Equity Historical Data

The historical data trend for Propanc Biopharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Propanc Biopharma Debt-to-Equity Chart

Propanc Biopharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

Get a 7-Day Free Trial

-0.40

-0.45

-0.22

-0.34

-0.18

Propanc Biopharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-0.30	-0.23	-0.18	-0.23	-0.29

Competitive Comparison of Propanc Biopharma's Debt-to-Equity

For the Biotechnology subindustry, Propanc Biopharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Propanc Biopharma's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Propanc Biopharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Propanc Biopharma's Debt-to-Equity falls into.

Propanc Biopharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Propanc Biopharma's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.527	+	0.019)	/	-3.117
	=	-0.18

Propanc Biopharma's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.975	+	0.043)	/	-3.564
	=	-0.29

Propanc Biopharma (OTCPK:PPCB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Propanc Biopharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Propanc Biopharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Propanc Biopharma (Propanc Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Propanc Biopharma Inc (OTCPK:PPCB) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

302, 6 Butler Street, Cambwerwell, VIC, AUS, 3124

Website

https://www.propanc.com

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Executives

Josef Zelinger	director	59 SEYMOUR ROAD, ELSTERNWICK C3 3185
Carlo M Campiciano	officer: CFO & Secretary	C/O. PROPANC BIOPHARMA,INC., 302, 6 BUTLER STREET, CAMBERWELL C3 3124
Julian Norman Kenyon	director	BEECHWOOD, EMBLEY LANE, EAST WELLOW, ROMSEY HAMPSHIRE X0 SO516DN
James Andrew Nathanielsz	director, officer: CEO, CFO, Secretary, Treasurer	1/76 SUMMERHILL ROAD, GLEN IRIS, VICTORIA C3 3146